RARE vs. SANA

In the year-to-date period, RARE achieves a -3.76% return, which is significantly higher than SANA's -42.40% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RARE Sharpe Ratio is 0.44, which is higher than the SANA Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of RARE and SANA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RARE nor SANA has paid dividends to shareholders.

The maximum RARE drawdown since its inception was -82.11%, smaller than the maximum SANA drawdown of -94.62%. Use the drawdown chart below to compare losses from any high point for RARE and SANA. For additional features, visit the drawdowns tool.

The current volatility for Ultragenyx Pharmaceutical Inc. (RARE) is 11.11%, while Sana Biotechnology, Inc. (SANA) has a volatility of 20.97%. This indicates that RARE experiences smaller price fluctuations and is considered to be less risky than SANA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Ultragenyx Pharmaceutical Inc. and Sana Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.